Related Experiment Video

Updated: Jul 16, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia

Alessandro Broccoli1,2, Lisa Argnani2, Laura Nanni1,2

  • 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli," Bologna, Italy.

Blood Advances
|September 22, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.1K

Related Experiment Videos

Last Updated: Jul 16, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

46.1K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.1K

Articles linked to this work by shared authors, journal, and citation graph.

Primary mediastinal B-cell lymphoma: a nationwide real-life retrospective study of first-line treatment approaches in Italy.

Haematologica·2026

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.

Clinical lymphoma, myeloma & leukemia·2026

Accuracy of percutaneous ultrasound-guided needle biopsy of abdominal lymph nodes for the diagnosis of malignant disease.

Oncology letters·2026

Development and Validation of the Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS): Protocol for an International Multistage Mixed Methods Study.

JMIR research protocols·2026

Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.

Blood advances·2026

First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations.

Blood·2026

Phase 1/2 study of favezelimab plus pembrolizumab in anti-PD-1-naive relapsed or refractory classical Hodgkin lymphoma.

Blood advances·2026

An Electronic Frailty Index Is Associated with Outcomes in Older Adults Receiving CAR-T Therapy.

Blood advances·2026

Brief Cognitive Assessment in Sickle Cell Care: Psychometric Properties of the RUDAS Across Two Languages.

Blood advances·2026

Platelet GPVI drives fibrotic lung remodeling.

Blood advances·2026

Late Venous Thromboembolic Events in Survivors of Childhood Cancer: A Report from the St Jude Lifetime Cohort Study.

Blood advances·2026

Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed/refractory multiple myeloma.

Blood advances·2026

Toll-like receptors 7 and 8 as therapeutic targets for human diseases.

International immunology·2026

Self-Assembling Peptide-Adjuvant Conjugate (SaPAC) Platform for Precision Cancer Immunotherapy.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Optimizing antibody-dependent cellular phagocytosis for cancer immunotherapy: mechanisms, constraints, and therapeutic strategies.

Journal of advanced research·2026

Jianwei Shoutai Pills enhances maternal-fetal immune tolerance via regulatory T cell modulation to ameliorate uterine aging-associated early pregnancy loss.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026

IL-1 signaling in cancer-associated fibroblasts: shaping fibroblast heterogeneity, tumor immunity, and therapeutic resistance.

Seminars in immunology·2026

Inflammatory intensity and stimulus type induce distinct miRNA regulatory programs in bovine endometrial epithelial cells.

Theriogenology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us